A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Exclusion Criteria

• •Prior or ongoing medical condition, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, would impact subject's safety and compliance with the study procedures.
• •Metastatic neoplasms within the five years prior to screening.
• •Presence of clinically relevant immunologic, hematologic, hepatic, cardiac, or renal disease at the time of screening as per investigator's clinical judgment.
• •Current untreated and unstable depressive disorder or a serious mood disorder requiring hospitalization.
• •History of prior suicide attempt or imminent risk of self-harm based on investigator's judgment or with a "yes" answer on item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).
• •Patients with history of confirmed stroke, known intracranial neoplasms, vascular malformations, or intracranial hemorrhage.
• •Subjects not deemed suitable for the surgical procedure as per the Neurosurgeon's judgment.
• •Any history of gene therapy, cell transplantation or any other experimental brain surgery.
• •Any RNA or DNA targeted HD specific investigational agents such as antisense oligonucleotides within 6 months prior to screening.
• •Subjects unable to tolerate or unwilling to undergo multiple lumbar punctures.
• •Participation in any clinical trial of an approved or non-approved investigational drug or intervention within 12 weeks or 5 half-lives whichever is longer prior to treatment.